GB0510142D0 - Novel compounds A1 - Google Patents

Novel compounds A1

Info

Publication number
GB0510142D0
GB0510142D0 GBGB0510142.3A GB0510142A GB0510142D0 GB 0510142 D0 GB0510142 D0 GB 0510142D0 GB 0510142 A GB0510142 A GB 0510142A GB 0510142 D0 GB0510142 D0 GB 0510142D0
Authority
GB
United Kingdom
Prior art keywords
novel compounds
novel
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0510142.3A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Addex Pharmaceuticals SA
Original Assignee
Addex Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Addex Pharmaceuticals SA filed Critical Addex Pharmaceuticals SA
Priority to GBGB0510142.3A priority Critical patent/GB0510142D0/en
Publication of GB0510142D0 publication Critical patent/GB0510142D0/en
Priority to EP06779742A priority patent/EP1896463A2/en
Priority to MX2007014405A priority patent/MX2007014405A/es
Priority to JP2008511819A priority patent/JP2008540634A/ja
Priority to US11/920,489 priority patent/US20090197897A1/en
Priority to UAA200714073A priority patent/UA92496C2/ru
Priority to CA002608012A priority patent/CA2608012A1/en
Priority to BRPI0610681-1A priority patent/BRPI0610681A2/pt
Priority to AU2006248649A priority patent/AU2006248649B2/en
Priority to NZ564253A priority patent/NZ564253A/en
Priority to PCT/IB2006/001674 priority patent/WO2006123249A2/en
Priority to KR1020077029357A priority patent/KR20080031676A/ko
Priority to EA200702468A priority patent/EA015263B1/ru
Priority to CN2006800251728A priority patent/CN101218232B/zh
Priority to IL187190A priority patent/IL187190A0/en
Priority to ZA200710277A priority patent/ZA200710277B/xx
Priority to NO20076479A priority patent/NO20076479L/no
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB0510142.3A 2005-05-18 2005-05-18 Novel compounds A1 Ceased GB0510142D0 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1
CN2006800251728A CN101218232B (zh) 2005-05-18 2006-05-17 噁二唑衍生物和它们作为代谢型谷氨酸受体的正变构调节剂的用途
AU2006248649A AU2006248649B2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
PCT/IB2006/001674 WO2006123249A2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
JP2008511819A JP2008540634A (ja) 2005-05-18 2006-05-17 新規オキサジアゾール誘導体及び代謝型グルタミン酸受容体の正のアロステリック調節因子としての当該誘導体の使用
US11/920,489 US20090197897A1 (en) 2005-05-18 2006-05-17 Novel Oxadiazole Derivatives and Their Use as Positive Allosteric Modulators of Metabotropic Glutamate Receptors
UAA200714073A UA92496C2 (ru) 2005-05-18 2006-05-17 Производные оксадиазола и их применение как положительных аллостерических модуляторов метаботропных глутаматных рецепторов
CA002608012A CA2608012A1 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
BRPI0610681-1A BRPI0610681A2 (pt) 2005-05-18 2006-05-17 derivados de oxadiazol, composição farmacêutica que os compreende e seu uso
EP06779742A EP1896463A2 (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
NZ564253A NZ564253A (en) 2005-05-18 2006-05-17 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
MX2007014405A MX2007014405A (es) 2005-05-18 2006-05-17 Novedosos derivados de oxadiazol y su uso como moduladores aloestericos positivos de los receptores de glutamato metabotropicos.
KR1020077029357A KR20080031676A (ko) 2005-05-18 2006-05-17 신규한 옥사디아졸 유도체 및 대사성 글루타메이트수용체의 양성 알로스테릭 조절자로서의 그것의 용도
EA200702468A EA015263B1 (ru) 2005-05-18 2006-05-17 Производные оксадиазола и их применение в качестве положительных аллостерических модуляторов метаботропных глутаматных рецепторов
IL187190A IL187190A0 (en) 2005-05-18 2007-11-06 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
ZA200710277A ZA200710277B (en) 2005-05-18 2007-11-28 Novel oxadiazole derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
NO20076479A NO20076479L (no) 2005-05-18 2007-12-17 Nye oksadiazolderivater og anvendelse derav som positive allosteriske metabotropiske modulatorer av glutamatreseptorer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0510142.3A GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1

Publications (1)

Publication Number Publication Date
GB0510142D0 true GB0510142D0 (en) 2005-06-22

Family

ID=34708380

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0510142.3A Ceased GB0510142D0 (en) 2005-05-18 2005-05-18 Novel compounds A1

Country Status (17)

Country Link
US (1) US20090197897A1 (https=)
EP (1) EP1896463A2 (https=)
JP (1) JP2008540634A (https=)
KR (1) KR20080031676A (https=)
CN (1) CN101218232B (https=)
AU (1) AU2006248649B2 (https=)
BR (1) BRPI0610681A2 (https=)
CA (1) CA2608012A1 (https=)
EA (1) EA015263B1 (https=)
GB (1) GB0510142D0 (https=)
IL (1) IL187190A0 (https=)
MX (1) MX2007014405A (https=)
NO (1) NO20076479L (https=)
NZ (1) NZ564253A (https=)
UA (1) UA92496C2 (https=)
WO (1) WO2006123249A2 (https=)
ZA (1) ZA200710277B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0510141D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
EP1893606A2 (en) * 2005-05-18 2008-03-05 Addex Pharma SA Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
JP2010533147A (ja) 2007-07-13 2010-10-21 アデックス ファルマ エス．エイ． 代謝調節型グルタミン酸レセプターのモジュレーターとしてのピラゾール誘導体
WO2009099177A1 (ja) * 2008-02-06 2009-08-13 Taisho Pharmaceutical Co., Ltd. アミノイミダゾール誘導体
US7790760B2 (en) 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2010098866A1 (en) 2009-02-27 2010-09-02 Supergen, Inc. Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors
EP2421370A4 (en) * 2009-04-23 2012-12-12 Merck Sharp & Dohme 2-alkyl-piperidine-mGluR5 receptor MODULATORS
US8772301B2 (en) 2009-12-18 2014-07-08 Sunovion Pharmaceuticals, Inc. Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
JP2013518085A (ja) 2010-02-01 2013-05-20 ノバルティス アーゲー ＣＲＦ−１受容体アンタゴニストとしてのピラゾロ［５，１ｂ］オキサゾール誘導体
AR080056A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de ciclohexil-amida como antagonistas de los receptores de crf
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
EP2668951B9 (en) 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
ES2617863T3 (es) 2012-06-04 2017-06-20 Actelion Pharmaceuticals Ltd. Derivados de bencimidazol-prolina
EA201500399A1 (ru) 2012-10-10 2015-09-30 Актелион Фармасьютиклз Лтд. Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона
CA2902135A1 (en) 2013-03-12 2014-09-18 Actelion Pharmaceuticals Ltd Azetidine amide derivatives as orexin receptor antagonists
SI3077391T1 (sl) 2013-12-04 2018-11-30 Idorsia Pharmaceuticals Ltd Uporaba benzimidazol-prolinskih derivatov
US10538516B2 (en) 2015-03-25 2020-01-21 National Center For Geriatrics And Gerontology Oxadiazole derivative and pharmaceutical containing same
US12590083B2 (en) 2019-01-25 2026-03-31 University Of Virginia Patent Foundation Inhibitors of spinster homolog 2 (SPNS2) for use in therapy
EP4210824A1 (en) * 2020-09-09 2023-07-19 University of Virginia Patent Foundation Inhibitors of spinster homolog 2 (spns2) for use in therapy
IL291418B2 (en) 2022-03-16 2024-05-01 Anima Biotech Inc Substances that function as modulators of cMYC-mRNA translation and their uses for cancer treatment

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK162087D0 (da) * 1987-03-31 1987-03-31 Ferrosan As Piperidinforbindelser, deres fremstilling og anvendelse
DE19643037A1 (de) * 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
US6107313A (en) * 1998-10-02 2000-08-22 Combichem, Inc. Dopamine receptor antagonists
CA2346537A1 (en) * 1998-10-07 2000-04-13 Gian Luca Araldi Monomeric and dimeric heterocycles, and therapeutic uses thereof
AU5891600A (en) * 1999-07-01 2001-01-22 Chemrx Advanced Technologies, Inc. Process for synthesizing oxadiazoles
KR100875222B1 (ko) * 1999-08-19 2008-12-19 아스트라제네카 아베 헤테로폴리사이클릭 화합물 및 간접 글루타메이트 수용체길항제로서의 그들의 용도
WO2001054503A1 (en) * 2000-01-28 2001-08-02 Akkadix Corporation Methods for killing nematodes and nematode eggs using 4-phenoxy-6-aminopyrimidine derivatives
MXPA03007513A (es) * 2001-02-21 2004-07-30 Nps Pharma Inc Compuestos heteropoliciclicos y su uso como antagonistas del receptor metabotropico de glutamato.
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
IL160700A0 (en) * 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
IL160701A0 (en) * 2001-09-21 2004-08-31 Mitsubishi Pharma Corp 3-substituted-4-pyrimidone derivatives
US6995144B2 (en) * 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2004014881A2 (en) * 2002-08-09 2004-02-19 Astra Zeneca Ab '1,2,4'oxadiazoles as modulators of metabotropic glutamate receptor-5
US7074809B2 (en) * 2002-08-09 2006-07-11 Astrazeneca Ab Compounds
PL375964A1 (en) 2002-09-06 2005-12-12 Janssen Pharmaceutica, N.V. Use of indolyl derivatives for the manufacture of a medicament for the treatment allergic rhinitis
PL1633724T3 (pl) * 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu
CA2519954A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Benzamide modulators of metabotropic glutamate receptors
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US20070185100A1 (en) * 2004-02-18 2007-08-09 Astrazeneca Ab Poly-heterocyclic compounds and their use as metabotropic glutamate receptor antagonists
CN101048397A (zh) * 2004-09-29 2007-10-03 三菱制药株式会社 作为τ蛋白激酶1抑制剂的6－（吡啶基）－4－嘧啶酮衍生物
GB0510143D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
EP1893606A2 (en) * 2005-05-18 2008-03-05 Addex Pharma SA Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510140D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B2
GB0510139D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
GB0510141D0 (en) * 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B3
GB0622202D0 (en) * 2006-11-07 2006-12-20 Addex Pharmaceuticals Sa Novel compounds

Also Published As

Publication number Publication date
KR20080031676A (ko) 2008-04-10
AU2006248649B2 (en) 2012-04-26
WO2006123249A2 (en) 2006-11-23
ZA200710277B (en) 2009-03-25
EP1896463A2 (en) 2008-03-12
EA200702468A1 (ru) 2008-06-30
CN101218232B (zh) 2012-06-27
JP2008540634A (ja) 2008-11-20
BRPI0610681A2 (pt) 2010-07-20
AU2006248649A1 (en) 2006-11-23
CA2608012A1 (en) 2006-11-23
NO20076479L (no) 2008-01-29
UA92496C2 (ru) 2010-11-10
EA015263B1 (ru) 2011-06-30
MX2007014405A (es) 2008-04-21
CN101218232A (zh) 2008-07-09
WO2006123249A3 (en) 2007-02-08
US20090197897A1 (en) 2009-08-06
NZ564253A (en) 2011-04-29
IL187190A0 (en) 2008-02-09

Similar Documents

Publication Publication Date Title
GB0510142D0 (en) Novel compounds A1
AP2007004171A0 (en) Novel compounds
EP1868612A4 (en) NOVEL CONNECTIONS
EP1868611A4 (en) NOVEL CONNECTIONS
GB0503955D0 (en) Novel compounds
GB0500140D0 (en) Novel compounds
EP1869026A4 (en) NEW CONNECTIONS
GB0500885D0 (en) Novel compounds
GB0501962D0 (en) Novel compounds
GB0500285D0 (en) Novel compounds
GB0500886D0 (en) Novel compounds
GB0500916D0 (en) Novel compounds
GB0500884D0 (en) Novel compounds
GB0500883D0 (en) Novel compounds
GB0500839D0 (en) Novel polyacetylen compounds
GB0500513D0 (en) Novel compounds
GB0500406D0 (en) Novel compounds
GB0501094D0 (en) Novel compounds
GB0501959D0 (en) Novel compounds
GB0500282D0 (en) Novel compounds
GB0500919D0 (en) Novel compounds
GB0500920D0 (en) Novel compounds
GB0500921D0 (en) Novel compounds
GB0500923D0 (en) Novel compounds
GB0500284D0 (en) Novel compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)